Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2167-2180

  Bui, Hung M ^a   Enis, David ^a   Robciuc, Marius R ^b   Nurmi, Harri J ^b   Cohen, Jennifer ^a   Chen, Mei ^a   Yang, Yiqing ^a   Dhillon, Veerpal ^a   Johnson, Kathy ^c   Zhang, Hong ^c   Kirkpatrick, Robert ^c   Traxler, Elizabeth ^a   Anisimov, Andrey ^b   Alitalo, Kari ^b   Kahn, Mark L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING EGF DOMAIN 1; CALCIUM BINDING PROTEIN; CHONDROITIN SULFATE; DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIF 3; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; ADAMTS PROTEIN; ADAMTS3 PROTEIN, HUMAN; CCBE1 PROTEIN, MOUSE; LIGAND; PEPTIDE HYDROLASE; PROCOLLAGEN N PROTEINASE; TUMOR SUPPRESSOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE; VEGFC PROTEIN, HUMAN; VEGFD PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS; ADULT; ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CELL LYSATE; CELL PROLIFERATION; CONDITIONED MEDIUM; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; EX VIVO STUDY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHANGIOGRAPHY; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; ZEBRA FISH; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DEFICIENCY; ENDOTHELIUM CELL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAMTS PROTEINS; ANIMALS; CALCIUM-BINDING PROTEINS; CELL PROLIFERATION; ENDOTHELIAL CELLS; HEK293 CELLS; HUMANS; LIGANDS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PEPTIDE HYDROLASES; PROCOLLAGEN N-ENDOPEPTIDASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84974588045     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83967     Document Type: Article

References (47)

1. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140(4):460-476.
2. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617-628.
3. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17(11):1371-1380.
4. Joukov V, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2):290-298.
5. Kaipainen A, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8):3566-3570.
6. Karkkainen MJ, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5(1):74-80.
7. Ober EA, et al. Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep. 2004;5(1):78-84.
8. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. 2000;67(2):295-301.
9. Gordon K, et al. Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. Circ Res. 2013;112(6):956-960.
10. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci U S A. 1996;93(21):11675-11680.
11. Achen MG, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95(2):548-553.
12. Koch M, et al. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J Pathol. 2009;219(3):356-364.
13. Astin JW, et al. Vegfd can compensate for loss of Vegfc in zebrafish facial lymphatic sprouting. Development. 2014;141(13):2680-2690.
14. Jeltsch M, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423-1425.
15. Rissanen TT, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92(10):1098-1106.
16. Saaristo A, Karkkainen MJ, Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci. 2002;979:94-110.
17. Joukov V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16(13):3898-3911.
18. Stacker SA, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem. 1999;274(45):32127-32136.
19. Alders M, et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet. 2009;41(12):1272-1274.
20. Hogan BM, et al. Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat Genet. 2009;41(4):396-398.
21. Connell F, et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet. 2010;127(2):231-241.
22. Bos FL, et al. CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res. 2011;109(5):486-491.
23. Hagerling R, et al. A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. EMBO J. 2013;32(5):629-644.
24. Zou Z, et al. The secreted lymphangiogenic factor CCBE1 is essential for fetal liver erythropoiesis. Blood. 2013;121(16):3228-3236.
25. Jeltsch M, et al. CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. Circulation. 2014;129(19):1962-1971.
26. Le Guen L, et al. Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis. Development. 2014;141(6):1239-1249.
27. Roukens MG, et al. Functional dissection of the CCBE1 protein: a crucial requirement for the collagen repeat domain. Circ Res. 2015;116(10):1660-1669.
28. Planas-Paz L, Strilic B, Goedecke A, Breier G, Fassler R, Lammert E. Mechanoinduction of lymph vessel expansion. EMBO J. 2012;31(4):788-804.
29. Colige A, et al. Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J Biol Chem. 2005;280(41):34397-34408.
30. Bylund L, Kytölä S, Lui WO, Larsson C, Weber G. Analysis of the cytogenetic stability of the human embryonal kidney cell line 293 by cytogenetic and STR profiling approaches. Cytogenet Genome Res. 2004;106(1):28-32.
31. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
32. Bolz H, Ramirez A, von Brederlow B, Kubisch C. Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family. Biochim Biophys Acta. 2001;1522(3):221-225.
33. Le Goff C, et al. Regulation of procollagen amino-propeptide processing during mouse embryogenesis by specialization of homologous ADAMTS proteases: insights on collagen biosynthesis and dermatosparaxis. Development. 2006;133(8):1587-1596.
34. Janssen L, et al. ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis. Angiogenesis. 2016;19(1):53-65.
35. McColl BK, et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med. 2003;198(6):863-868.
36. McColl BK, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J. 2007;21(4):1088-1098.
37. Yang Y, Oliver G. Development of the mammalian lymphatic vasculature. J Clin Invest. 2014;124(3):888-897.
38. Anisimov A, et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 2009;104(11):1302-1312.
39. Romer J, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2(3):287-292.
40. Alders M, et al. Evaluation of clinical manifestations in patients with severe lymphedema with and without CCBE1 mutations. Mol Syndromol. 2013;4(3):107-113.
41. Alders M, et al. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. Hum Genet. 2014;133(9):1161-1167.
42. Leppanen VM, et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci U S A. 2013;110(32):12960-12965.
43. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210-221.
44. Choi I, et al. Visualization of lymphatic vessels by Prox1-promoter directed GFP reporter in a bacterial artificial chromosome-based transgenic mouse. Blood. 2011;117(1):362-365.
45. Nurmi H, Saharinen P, Zarkada G, Zheng W, Robciuc MR, Alitalo K. VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. EMBO Mol Med. 2015;7(11):1418-1425.
46. Baldwin ME, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25(6):2441-2449.
47. Enholm B, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001;88(6):623-629.